乳腺癌抗肿瘤血管治疗的临床进展

doi:10.11904/j.issn.1002-3070.2019.05.015

Abstract

Abstract: Angiogenesis is one of key conditions for tumorigenesis.Anti-angiogenic drugs block angiogenesis and are considered to be an important breakthrough in the treatment of various types of cancer,especially advanced cancer.Anti-angiogenic drugs have shown good efficacy in combination chemotherapy in patients with advanced gastric cancer,colorectal cancer,prostate cancer and advanced liver cancer.However,many studies have shown contradictory results in breast cancer,causing controversy about the value of this drug.In this article,we review the evidence for anti-angiogenic therapy options for breast cancer,discuss possible factors limiting the effectiveness of anti-angiogenic drugs,and suggest future research on these therapies for the treatment of breast cancer.

Key words: Anti-angiogenic drugs, Breast cancer, Bevacizumab, Predictive biomarker

CLC Number:

R737.9

LI Lei, ZHANG Qingyuan. Clinical progress of anti-tumor vascular therapy for breast cancer[J]. Journal of Practical Oncology, 2019, 33(5): 461-465.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2019.05.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2019/V33/I5/461

References

1 Fidler IJ,Ellis LM.The implications of angiogenesis for the biology and therapy of cancer metastasis[J].Cell,1994,79(2):185-188.
2 Miller K,Wang M,Gralow J,et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J].N Engl J Med,2007,357(26):2666-2676.
3 Aparicio-Gallego G,Blanco M,Figueroa A,et al.New insights into molecular mechanisms of sunitinib-associated side effects[J].Mol Cancer Ther,2011,10:2215-2223.
4 Gotink KJ,Verheul HMW.Anti-angiogenic tyrosine kinase inhibitors:what is their mechanism of action?[J].Angiogenesis,2010,13:1-14.
5 Tan AR,Buyse ME,Rastogi P,et al.NSABP FB-6:phase II trial of weekly paclitaxel(WP)and pazopanib following doxorubicin and cyclophosphamide(AC)as neoadjuvant therapy for HER2-negative locally advanced breast cancer(LABC)[J].J Surg Oncol,2012,95(7):530-531.
6 Miller K,O'Neill A,Dang C,et al.Bevacizumab(B)in the adjuvant treatment of breast cancer-first toxicity results from eastern cooperative oncology group trial E5103[J].Cancer Res,2012,72(24):331-337.
7 Palazzo A,Dellapasqua S,Munzone E,et al.Phase II Trial of bevacizumab plus weekly paclitaxel,carboplatin,and metronomic cyclophosphamide with or without trastuzumab and endocrinetherapy as preoperative treatment of inflammatory breastcancer[J].Clin Breast Cancer,2018,18(4):328-335.
8 Dickler MN,Barry WT,Cirrincione CT,et al.Phase III trialevaluating letrozole as first-line endocrine therapy with or without bevacizumab for thetreatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer:CALGB 40503(alliance)[J].J Clin Oncol,2016,34(22):2602-2609.
9 Martín M,Al E.Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer-First efficacy results from the LEA study[J].Cancer Res,2012,72(24):1-7.
10 Sooyoung S,Yoojin N.Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer:a meta-analysis of randomized controlled trials[J].Ther Clin Risk Manage,2018,14:833-847.
11 Miles DW,De Haas SL,Dirix LY,et al.Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for Her2-negative metastatic breast cancer[J].Br J Cancer,2013,108(5):1052-1060.
12 Cutsem EV,Haas SD,Kang YK,et al.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:a biomarker evaluation from the AVAGAST randomized phase III trial[J].J Clin Oncol,2012,30(17):2119-2127.
13 Melanie J,Müller V,Vettorazzi E,et al.Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab:a biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial[J].Clin Oncol,2016,34:1150-1155.
14 Gampenrieder SP,Rinnerthaler G,Hackl H,et al.DNA methylation signatures predicting bevacizumab efficacy in metastatic breast cancer[J].Theranostics,2018,8(8):2278-2288.
15 Desai J,Gurney H,Pavlakis N,et al.Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor:Recommendations for patient management[J].Asia-Pac J Clin Oncol,2010,3(4):167-176.
16 Crown JP,Diéras V,Staroslawska E,et al.Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer[J].J Clin Oncol,2013,31(23):2870.
17 Curigliano G,Pivot X,Cortés J,et al.Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer[J].Breast,2013,22(5):650-656.
18 Yardley DA,Shipley DL,Peacock NW,et al.Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer[J].Breast Cancer Res Treat,2015,152(3):557-567.
19 Elgebaly A,Menshawy A,El Ashal G,et al.Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer:A systematic review and meta-analysis[J].Breast Dis,2016,36(2/3):91-101.
20 Zafrakas M,Papasozomenou P,Emmanouilides C.Sorafenib in breast cancer treatment:A systematic review and overview of clinical trials[J].World J Clin Oncol,2016,7(4):331-336.
21 Chen J,Tian CX,Yu M,et al.Efficacy and safety profile of combining sorafenib with chemotherapy in patients with HER2-negative advanced breast cancer:a meta-analysis[J].J Breast Cancer,2014,17(1):61-68.
22 Zafrakas M,Papasozomenou P,Emmanouilides C.Sorafenib in breast cancer treatment:A systematic review and overview of clinical trials[J].World J Clin Oncol,2016,7(4):331-336.
23 周陈建,赵嫏嬛,胡国新.帕唑帕尼的临床应用和药品不良反应的研究进展[J].药学实践杂志,2016,34(6):497-500.
24 Criscitiello C,Gelao L,Viale G,et al.Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy[J].Expert Opin Invest Drugs,2014,23(5):599-610.
25 Cheng TF,Ou-Yang F,Lapke N,et al.Pazopanib Sensitivity in a patient with Breast cancer and FGFR1 amplification[J].JNCCN,2017,15(12):1456-1459.
26 Casak SJ,Fashoyinaje I,Lemery SJ,et al.FDA Approval summary:ramucirumab for gastric cancer[J].Clin Cancer Res,2015,21(15):3372-3376.
27 Fala L.Cyramza(Ramucirumab)approved for the treatment of advanced gastric cancer and metastatic non-small-cell lung cancer[J].Am Health Drug Benefits,2015,8(Spec Feature):49-53.
28 Mackey JR,Ramosvazquez M,Lipatov O,et al.Primary Results of ROSE/TRIO-12,a aandomized placebo-controlledphase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer[J].J Clin Oncol,2015,33(2):141-148.
29 Schneider BP,Li L,Shen F,et al.Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100[J].Br J Cancer,2014,111(6):1241-1248.
30 Zhang H.Apatinib for molecular targeted therapy in tumor[J].Drug Des Dev Ther,2015,9:6075-6081.
31 Hu X,Zhang J,Xu B,et al.Multicenterphase II study of apatinib,a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple negative breast cancer[J].Int J Cancer,2014,135(8):1961-1969.
32 Hu X,Cao J,Hu W,et al.Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer[J].BMC Cancer,2014,14:820.
33 查天麒,卢凯华.阿帕替尼临床应用的研究进展[J].江苏医药,2017,43(13):958-961.

[1]	SHI Manru, E Mingyan. Effect of delayed radiotherapy on the prognosis of patients with different molecular subtypes of breast cancer [J]. Journal of Practical Oncology, 2019, 33(5): 431-435.
[2]	WANG Yu, QIAO Juanjuan, ZHANG Lei, LIU Siwei, YANG Shucai. The role of steroid hormones in breast cancer and its effect on cancer stem cells [J]. Journal of Practical Oncology, 2019, 33(5): 466-470.
[3]	LIU Eryu, YANG Hao, LIANG Guohua, ZHAO Yanfang, ZHAO Wenhui. Action for CDK4/6 inhibitors combined with mTOR inhibitors in breast cancer and its mechanism [J]. Journal of Practical Oncology, 2019, 33(5): 476-480.
[4]	AN Weiwei, TANG Yali, ZHAO Lianhua, YANG Yue, WANG Xinling. Polyphenylene-polysaccharide complex from pinus koraiensis extract induces apoptosis in human breast cancer MCF-7 cells [J]. Journal of Practical Oncology, 2019, 33(4): 289-293.
[5]	HU Lin, SHEN Jia. Growth differentiation factor 15 plays a role in predicting and monitoring the cardiotoxicity of epirubicin/cyclophosphamide-docetaxel-trastuzumab in the treatment of patients with HER-2 positive breast cancer [J]. Journal of Practical Oncology, 2019, 33(4): 340-345.
[6]	MA Yan, HE Hong, WANG Sainan. Clinical study of docetaxel in the treatment of metastatic breast cancer in different age groups [J]. Journal of Practical Oncology, 2019, 33(4): 352-356.
[7]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[8]	LI Shuo,ZHANG Nannan,LI Liangliang,LONG Zhiping,YIN Huihui,ZHAO Yashuang,WANG Fan. Relationship between PDE4C gene methylation in peripheral blood leukocytes,interaction of environmental factors and pathogenesis of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 233-238.
[9]	CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.
[10]	SUN Jianghong, HAO Mingzhu, JIANG Dan, GUO Fei, LI Xiaomei. FFDM differential diagnosis of mastitis,benign hyperplasia and breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 139-141.
[11]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[12]	FANG Lin, LIU Chao, ZHANG Chunhui, ZHANG Yanqiao. Research status and treatment strategies of maintenance therapy for metastatic colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 173-178.
[13]	MA Zhingying, SHANG Naijian, CAI Miaotian, SHEN Yang, JIANG Zhiyun. Correlation between HER-2 receptor of progesterone and estrogen receptor-positive breast cancer and mammography imaging & clinicopathological features [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 47-51.
[14]	HE Xu, YE shangmian, DONG dandan, LI Ke. The expression of HLA-G in breast cancer and its significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 410-414.
[15]	LI Wenqi,GENG Jingshu. Research progress of RAS,RAF mutation and MSI status in the treatment of colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 371-376.

Clinical progress of anti-tumor vascular therapy for breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments